Literature DB >> 21686567

Asymptomatic presentation of mesalamine-induced lung injury in an adolescent with Crohn disease.

Rafael Cilloniz1, Sarah Elizabeth Chesrown, Regino P Gonzalez-Peralta.   

Abstract

The present report describes the case of a 14-year-old boy receiving mesalamine for Crohn disease who was discovered to have incidental pulmonary infiltrates on chest radiograph and CT scan shortly after increasing the dose of this medication. Despite the significant radiographic abnormalities, he had no respiratory symptoms. He had normal oxygenation and normal pulmonary function tests including spirometry, lung volumes and diffusion capacity. Transbronchial biopsies showed patchy interstitial fibrosis with ill-defined non-necrotising granulomas and lymphoid aggregates. Pulmonary infiltrates resolved within 6 weeks of discontinuation of mesalamine and the addition of low-dose daily corticosteroids. This case likely represents an asymptomatic "early stage" of mesalamine-induced lung injury preceding the onset of symptoms. Alternatively, mesalamine may induce asymptomatic lung injury more commonly than is presently suspected. To the best of our knowledge this is the first time this complication has been reported without respiratory symptoms.

Entities:  

Year:  2009        PMID: 21686567      PMCID: PMC3027507          DOI: 10.1136/bcr.09.2008.0908

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  19 in total

1.  Lung disease associated with orally administered mesalamine for ulcerative colitis.

Authors:  M A Reinoso; K W Schroeder; R J Pisani
Journal:  Chest       Date:  1992-05       Impact factor: 9.410

2.  Lung function in patients with inflammatory bowel disease.

Authors:  N Tzanakis; D Bouros; M Samiou; P Panagou; J Mouzas; O Manousos; N Siafakas
Journal:  Respir Med       Date:  1998-03       Impact factor: 3.415

Review 3.  Can a drug-induced pulmonary hypersensitivity reaction be dose-dependent? A case with mesalamine.

Authors:  P Sossai; M G Cappellato; S Stefani
Journal:  Mt Sinai J Med       Date:  2001-11

4.  Mesalamine induces manganese superoxide dismutase in rat intestinal epithelial cell lines and in vivo.

Authors:  J F Valentine
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2001-10       Impact factor: 4.052

5.  Respiratory impairment in inflammatory bowel disease: does it vary with disease activity?

Authors:  J G Douglas; C F McDonald; M J Leslie; J Gillon; G K Crompton; G J McHardy
Journal:  Respir Med       Date:  1989-09       Impact factor: 3.415

Review 6.  Advances in drug therapy for inflammatory bowel disease.

Authors:  M A Peppercorn
Journal:  Ann Intern Med       Date:  1990-01-01       Impact factor: 25.391

7.  Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remission.

Authors:  K R Herrlinger; M K Noftz; K Dalhoff; D Ludwig; E F Stange; K Fellermann
Journal:  Am J Gastroenterol       Date:  2002-02       Impact factor: 10.864

Review 8.  Mesalazine-induced eosinophilic pneumonia.

Authors:  K Tanigawa; K Sugiyama; H Matsuyama; H Nakao; K Kohno; Y Komuro; Y Iwanaga; K Eguchi; M Kitaichi; H Takagi
Journal:  Respiration       Date:  1999       Impact factor: 3.580

Review 9.  Mesalamine-induced lung toxicity.

Authors:  A Bitton; M A Peppercorn; J P Hanrahan; M P Upton
Journal:  Am J Gastroenterol       Date:  1996-05       Impact factor: 10.864

10.  Mesalazine: a global safety evaluation.

Authors:  R Brimblecombe
Journal:  Scand J Gastroenterol Suppl       Date:  1990
View more
  4 in total

Review 1.  Pulmonary manifestations of inflammatory bowel disease.

Authors:  Xiao-Qing Ji; Li-Xia Wang; De-Gan Lu
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

Review 2.  Pulmonary manifestations of Crohn's disease.

Authors:  De-Gan Lu; Xiao-Qing Ji; Xun Liu; Hong-Jia Li; Cai-Qing Zhang
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

3.  Gastroenterology case report of mesalazine-induced cardiopulmonary hypersensitivity.

Authors:  José Ferrusquía; Isabel Pérez-Martínez; Ricardo Gómez de la Torre; María Luisa Fernández-Almira; Ruth de Francisco; Luis Rodrigo; Sabino Riestra
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

4.  Acute respiratory failure secondary to mesalamine-induced interstitial pneumonitis.

Authors:  Albin Abraham; Ali Karakurum
Journal:  BMJ Case Rep       Date:  2013-08-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.